We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S.
Read MoreHide Full Article
AbbVie Inc. (ABBV - Free Report) announced that its oncology candidate, ABT-414, has been granted Rare Pediatric Disease Designation in the U.S. for the treatment of pediatric patients with epidermal growth factor receptor (EGFR)-amplified diffuse intrinsic pontine glioma (DIPG) – highly aggressive and difficult-to-treat brain tumors found at the base of the brain.
The designation was granted based on a proposed pediatric sub-study ‘nested’ within the ongoing phase II study on ABT-414 in adults with recurrent EGFR-amplified glioblastoma that is being conducted in collaboration with the European Organization for Research and Treatment of Cancer.
In 2014, ABT-414 received Orphan Drug Designation in both the U.S. and the EU for the treatment of adult glioblastoma and glioma, respectively.
We note that AbbVie is developing ABT-414 with certain components in-licensed from Life Science Pharmaceuticals, Inc. and Seattle Genetics .
According to the press release issued by AbbVie, brainstem tumors comprise approximately 10–15% of all pediatric brain tumors. Each year, approximately 200–400 children are affected by DIPG in the U.S.
Given the limited options for the treatment of glioblastoma and glioma, there is urgent need for new treatments in this field. If successfully developed and commercialized, ABT-414 will be able to boost the company’s portfolio.
Currently available drugs for the treatment of glioblastoma include Avastin, Tamodar and Gliadel.
AbbVie currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include GW Pharmaceuticals plc and Innoviva, Inc. (INVA - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S.
AbbVie Inc. (ABBV - Free Report) announced that its oncology candidate, ABT-414, has been granted Rare Pediatric Disease Designation in the U.S. for the treatment of pediatric patients with epidermal growth factor receptor (EGFR)-amplified diffuse intrinsic pontine glioma (DIPG) – highly aggressive and difficult-to-treat brain tumors found at the base of the brain.
The designation was granted based on a proposed pediatric sub-study ‘nested’ within the ongoing phase II study on ABT-414 in adults with recurrent EGFR-amplified glioblastoma that is being conducted in collaboration with the European Organization for Research and Treatment of Cancer.
In 2014, ABT-414 received Orphan Drug Designation in both the U.S. and the EU for the treatment of adult glioblastoma and glioma, respectively.
ABBVIE INC Price
ABBVIE INC Price | ABBVIE INC Quote
We note that AbbVie is developing ABT-414 with certain components in-licensed from Life Science Pharmaceuticals, Inc. and Seattle Genetics .
According to the press release issued by AbbVie, brainstem tumors comprise approximately 10–15% of all pediatric brain tumors. Each year, approximately 200–400 children are affected by DIPG in the U.S.
Given the limited options for the treatment of glioblastoma and glioma, there is urgent need for new treatments in this field. If successfully developed and commercialized, ABT-414 will be able to boost the company’s portfolio.
Currently available drugs for the treatment of glioblastoma include Avastin, Tamodar and Gliadel.
AbbVie currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include GW Pharmaceuticals plc and Innoviva, Inc. (INVA - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>